Base de dados : MEDLINE
Pesquisa : D02.065.884.730 [Categoria DeCS]
Referências encontradas : 3834 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 384 ir para página                         

  1 / 3834 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28456475
[Au] Autor:Molinuevo MS; Fernández JM; Cortizo AM; McCarthy AD; Schurman L; Sedlinsky C
[Ad] Endereço:Laboratorio de Investigación en Osteopatías y Metabolismo Mineral, Facultad de Ciencias Exactas, Universidad Nacional de La Plata. 47 y 115, (1900) La Plata, Argentina.
[Ti] Título:Advanced glycation end products and strontium ranelate promote osteogenic differentiation of vascular smooth muscle cells in vitro: Preventive role of vitamin D.
[So] Source:Mol Cell Endocrinol;450:94-104, 2017 Jul 15.
[Is] ISSN:1872-8057
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Advanced glycation end products (AGE) have been demonstrated to induce the osteogenic trans-differentiation of vascular smooth muscle cells (VSMC). Strontium ranelate (SR) is an anti-osteoporotic agent that has both anti-catabolic and anabolic actions on bone tissue. However, in the last years SR has been associated with an increase of cardiovascular risk. We hypothesize that SR can increase the osteoblastic trans-differentiation of VSMC and the induction of extracellular calcifications, an effect that could be potentiated in the presence of AGE and inhibited by simultaneous administration of vitamin D. The present results of our in vitro experiments demonstrate that AGE and SR alone or in combination, stimulate L-type calcium channels, causing an increase in reactive oxygen species and activation of both ERK and NFkB, with the final effect of promoting the osteogenic shift of VSMC. Importantly, these in vitro effects of AGE and/or SR can be prevented by co-incubation with vitamin D.
[Mh] Termos MeSH primário: Diferenciação Celular/efeitos dos fármacos
Produtos Finais de Glicação Avançada/farmacologia
Músculo Liso Vascular/citologia
Miócitos de Músculo Liso/citologia
Osteogênese/efeitos dos fármacos
Tiofenos/farmacologia
Vitamina D/farmacologia
[Mh] Termos MeSH secundário: Animais
Ácido Ascórbico/farmacologia
Contagem de Células
Movimento Celular/efeitos dos fármacos
Subunidade alfa 1 de Fator de Ligação ao Core/metabolismo
Masculino
Modelos Biológicos
Miócitos de Músculo Liso/efeitos dos fármacos
Miócitos de Músculo Liso/metabolismo
Nifedipino/farmacologia
Estresse Oxidativo/efeitos dos fármacos
Ratos Sprague-Dawley
Espécies Reativas de Oxigênio/metabolismo
Sulfassalazina/farmacologia
Vitamina E/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Core Binding Factor Alpha 1 Subunit); 0 (Glycation End Products, Advanced); 0 (Reactive Oxygen Species); 0 (Thiophenes); 04NQ160FRU (strontium ranelate); 1406-16-2 (Vitamin D); 1406-18-4 (Vitamin E); 3XC8GUZ6CB (Sulfasalazine); I9ZF7L6G2L (Nifedipine); PQ6CK8PD0R (Ascorbic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170501
[St] Status:MEDLINE


  2 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29197623
[Au] Autor:Ommati MM; Heidari R; Jamshidzadeh A; Zamiri MJ; Sun Z; Sabouri S; Wang J; Ahmadi F; Javanmard N; Seifi K; Mousapour S; Yeganeh BS
[Ad] Endereço:Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Animal Sciences, School of Agriculture, Shiraz University, Shiraz, Iran; Shanxi Key Laboratory of Ecological Animal Science and Environmental Medicine, Shanxi, Agricultural University, Taigu,
[Ti] Título:Dual effects of sulfasalazine on rat sperm characteristics, spermatogenesis, and steroidogenesis in two experimental models.
[So] Source:Toxicol Lett;284:46-55, 2018 Mar 01.
[Is] ISSN:1879-3169
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:There are reports of sulfasalazine (Salazosulfapyridine; SASP)-induced reproductive toxicity, but there it is not known whether the SASP molecule or its intestinal metabolites are responsible for this effect. Rats received SASP (150, 300, and 600mg/kg) for 60 consecutive days (in vivo). Additionally, epididymal sperm was isolated and incubated with SASP (10µM-1600µM) (in vitro). Markers of oxidative stress, mitochondrial function, and sperm functionality, along with testis histopathology as well as several steroidogenic genes and proteins, including steroidogenic acute regulatory (StAR) protein, cytochrome P450 side chain cleavage enzyme (P450scc; Cyp11a), 3ß-hydroxysteroid dehydrogenase (3ß-HSD), 17ß-hydroxysteroid dehydrogenase (17ß-HSD) were measured. SASP toxicity was evident as shown by severe testicular histopathological alterations, along with poor sperm parameters and increased markers of oxidative stress. Plasma testosterone level and steroidogenesis-related gene and protein (StAR, 3-beta-HSD, 17-beta-HSD) expressions, as well as mitochondrial membrane potential, were significantly decreased at high doses of SASP (in vivo). Interestingly, in vitro treatment of sperm with SASP not only caused no significant detrimental effect on rat sperm but also increased parameters of sperm functionality and decreased markers of oxidative stress. SASP had paradoxical actions on the rat sperm in these experimental models. The findings might be useful in understanding the mechanism(s) of SASP-induced reproductive toxicity. The present findings have opened a new molecular window into the relationship between disrupted steroidogenesis and mammalian reproduction indices and also are vital regarding clinical administration of SASP and human reproductive health.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/toxicidade
Hormônios Esteroides Gonadais/metabolismo
Espermatogênese/efeitos dos fármacos
Espermatozoides/efeitos dos fármacos
Sulfassalazina/toxicidade
Testículo/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Biomarcadores/metabolismo
Relação Dose-Resposta a Droga
Masculino
Estresse Oxidativo/efeitos dos fármacos
Ratos Sprague-Dawley
Espermatozoides/metabolismo
Espermatozoides/patologia
Testículo/metabolismo
Testículo/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Biomarkers); 0 (Gonadal Steroid Hormones); 3XC8GUZ6CB (Sulfasalazine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171204
[St] Status:MEDLINE


  3 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29369189
[Au] Autor:Bartal C; Sagy I; Barski L
[Ti] Título:Drug-induced eosinophilic pneumonia: A review of 196 case reports.
[So] Source:Medicine (Baltimore);97(4):e9688, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVE: Eosinophilic pneumonia (EP) is an important subset of patients who present with pulmonary infiltrates and eosinophilia (PIE). EP is classified by chronicity and etiology and drug-induced EP is the main cause of secondary EP. The primary goal of this review was to examine all the case reports published since the syndrome was defined in 1990. It remains unclear whether acute or chronic EP (AEP or CEP) represent different diseases, and the secondary goal of this review is to determine if there are factors that may help distinguish these 2 entities. METHODS: PubMed (MEDLINE and Medical Subject Headings) was searched for case reports of drug-induced EP or PIE syndrome published between 1990 and 2017. Case reports were only included if the diagnostic criteria for AEP or CEP were fulfilled. For each case, data were extracted pertaining to age, sex, type of medication associated with the disease, time from the onset of symptoms to diagnosis, eosinophil counts in the blood, eosinophil fractions in bronchoalveolar lavage (BAL) fluid, initial chest radiograph and computed tomography results, use of mechanical ventilation, and use of steroid treatment and recurrence. RESULTS: We found 196 case reports describing drug-induced EP. The leading cause was daptomycin. From our review, we found that AEP is more common in younger patients with no gender preference. Eosinophilia in the blood at the time of diagnosis characterized only the CEP patients (80% in CEP vs. 20% in AEP). Abnormal findings on radiographic imagine was similar in both syndromes. A significant portion of AEP patients (20%) presented with acute respiratory failure requiring mechanical ventilation. Most patients with EP were treated with steroids with a higher rate of relapse observed in patients with CEP. CONCLUSION: AEP is a much more fulminant and severe disease than the gradual onset and slowly progressive nature of CEP. The pathogenesis of AEP and CEP remains unclear. However, there is significant clinical overlap among AEP and CEP that are associated with drug toxicity, suggesting the possibility that AEP and CEP are distinct clinical presentations that share a common pathogenic pathway.
[Mh] Termos MeSH primário: Antibacterianos/efeitos adversos
Anti-Inflamatórios não Esteroides/efeitos adversos
Eosinofilia Pulmonar/induzido quimicamente
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Doença Crônica
Daptomicina/efeitos adversos
Eosinófilos
Feminino
Seres Humanos
Masculino
Mesalamina/efeitos adversos
Meia-Idade
Minociclina/efeitos adversos
Eosinofilia Pulmonar/sangue
Sulfassalazina/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Anti-Inflammatory Agents, Non-Steroidal); 3XC8GUZ6CB (Sulfasalazine); 4Q81I59GXC (Mesalamine); FYY3R43WGO (Minocycline); NWQ5N31VKK (Daptomycin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009688


  4 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28957556
[Au] Autor:Bergstra SA; Landewé RBM; Huizinga TWJ; Allaart CF
[Ad] Endereço:Department of Rheumatology, Leiden University Medical Center, Leiden.
[Ti] Título:Rheumatoid arthritis patients with continued low disease activity have similar outcomes over 10 years, regardless of initial therapy.
[So] Source:Rheumatology (Oxford);56(10):1721-1728, 2017 Oct 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: To compare 10-year disease outcomes of RA patients who have continuous low disease activity and are on MTX with or without initial combination therapy with infliximab or prednisone and SSZ. Methods: Recent-onset RA patients from the Behandel Strategieen (BeSt) (Dutch acronym for Treatment Strategies) study with 10 years of follow-up were analysed. Treatment was tightly controlled, targeted at DAS ⩽ 2.4. The selected patients had low disease activity from 6 months until 10 years and therefore did not intensify treatment. Patients were grouped into those receiving MTX monotherapy and those receiving initial combination therapy. Between-group differences over time were compared, using (generalized) linear mixed model analyses, for the outcomes DAS, HAQ, ESR, visual analogue scale patient global health, percentage of patients in (drug-free) remission and percentage of patients with Sharp/van der Heijde score progression ⩾5. Results: At 10 years, 28/247 (11%) patients on MTX monotherapy (some tapered to drug free) had continued DAS ⩽ 2.4 compared with 68/261 (26%) patients on combination therapy (all tapered to monotherapy or drug free). No between-group differences in continuous responders were found over time, except for a higher percentage of patients in drug-free remission after MTX monotherapy. Significant group-time interactions were found for DAS, ESR and visual analogue scale patient global health, but the results seem clinically negligible. Conclusion: More patients achieved continuous low disease activity on initial prednisone or infliximab combination therapy than on initial MTX monotherapy, but there appeared to be no additional benefits. Regardless of induction therapy, patients with continuous low disease activity have similar long-term outcomes, with only a higher proportion of patients in drug-free remission after MTX monotherapy.
[Mh] Termos MeSH primário: Antirreumáticos/administração & dosagem
Artrite Reumatoide/tratamento farmacológico
Metotrexato/administração & dosagem
Índice de Gravidade de Doença
[Mh] Termos MeSH secundário: Adulto
Idoso
Artrite Reumatoide/patologia
Progressão da Doença
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Infliximab/administração & dosagem
Modelos Lineares
Masculino
Meia-Idade
Países Baixos
Prednisona/administração & dosagem
Indução de Remissão
Sulfassalazina/administração & dosagem
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antirheumatic Agents); 3XC8GUZ6CB (Sulfasalazine); B72HH48FLU (Infliximab); VB0R961HZT (Prednisone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171006
[Lr] Data última revisão:
171006
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex236


  5 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28923326
[Au] Autor:Cetin C; Erdogan AM; Dincel GC; Bakar B; Kisa U
[Ad] Endereço:Kirikkale University, Faculty of Medicine, Kirikkale, Turkey.
[Ti] Título:Effects of Sulphasalazine in Cerebral Ischemia Reperfusion Injury in Rat.
[So] Source:Arch Med Res;48(3):247-256, 2017 Apr.
[Is] ISSN:1873-5487
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Management of cerebral ischemia/reperfusion (I/R) injury is still difficult process today. AIMS OF THE STUDY: Aim of present study was to investigate therapeutic properties of sulfasalazine in cerebral transient I/R injury in rat. METHODS: Except Control group (n = 5), 20 Wistar albino rats were allocated for acute and chronic stage investigation of I/R injury, and temporary aneurysm clips were attempted to both internal carotid arteries for thirty min. Four hours later, 40 mg/kg once a day sulfasalazine was administered to animals of SL-A and SL-C groups, orally. Animals were decapitated, following which pyknotic and necrotic neuronal cells, perivascular edema, irregularities of intercellular organization (IIO) of hippocampal regions, and cortical necrotic neurons of parietal lobe were counted or scaled histopathologically. Tissue malonyldialdehyde (MDA), myeloperoxidation (MPO), total nitrite/nitrate (NO), interleukin 1-beta (IL-1ß), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) level values were evaluated biochemically. RESULTS: Sulfasalazine could reduce perivascular edema, IIO, cortical and hippocampal neuronal cell death in both stages. It could decrease MDA in acute stage, but not reduce IL-1ß, IL-6, MPO, NO, and TNFα levels. It could increase IL-1ß levels in chronic stage but not affect to IL-6, MPO, MDA, NO, TNF-α levels. CONCLUSION: Sulfasalazine could improve histopathological architecture of hypoxic tissue in both stages of I/R injury in rat. It could inhibit lipid peroxidation cascades just in acute stage. These results suggested that therapeutic mechanisms of sulfasalazine in cerebral I/R injury should be investigated by using more specific laboratory methods in future studies.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Isquemia Encefálica/tratamento farmacológico
Traumatismo por Reperfusão/tratamento farmacológico
Sulfassalazina/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Edema Encefálico/tratamento farmacológico
Edema Encefálico/metabolismo
Isquemia Encefálica/metabolismo
Isquemia Encefálica/patologia
Córtex Cerebral/efeitos dos fármacos
Córtex Cerebral/metabolismo
Córtex Cerebral/patologia
Hipocampo/efeitos dos fármacos
Hipocampo/metabolismo
Hipocampo/patologia
Interleucina-1beta/metabolismo
Interleucina-6/metabolismo
Peroxidação de Lipídeos/efeitos dos fármacos
Masculino
Malondialdeído/metabolismo
Óxido Nítrico/metabolismo
Peroxidase/metabolismo
Ratos Wistar
Traumatismo por Reperfusão/metabolismo
Traumatismo por Reperfusão/patologia
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Interleukin-1beta); 0 (Interleukin-6); 0 (Tumor Necrosis Factor-alpha); 31C4KY9ESH (Nitric Oxide); 3XC8GUZ6CB (Sulfasalazine); 4Y8F71G49Q (Malondialdehyde); EC 1.11.1.7 (Peroxidase)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170920
[St] Status:MEDLINE


  6 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28863153
[Au] Autor:Walsh AM; Wechalekar MD; Guo Y; Yin X; Weedon H; Proudman SM; Smith MD; Nagpal S
[Ad] Endereço:Immunology, Janssen Research and Development, LLC., Spring House, Pennsylvania, United States of America.
[Ti] Título:Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.
[So] Source:PLoS One;12(9):e0183928, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: This study sought to investigate the genome-wide transcriptional effects of a combination of disease modifying anti-rheumatic drugs (tDMARD; methotrexate, sulfasalazine and hydroxychloroquine) in synovial tissues obtained from early rheumatoid arthritis (RA) patients. While combination DMARD strategies have been investigated for clinical efficacy, very little data exists on the potential molecular mechanism of action. We hypothesized that tDMARD would impact multiple biological pathways, but the specific pathways were unknown. METHODS: Paired synovial biopsy samples from early RA patients before and after 6 months of tDMARD therapy were collected by arthroscopy (n = 19). These biopsies as well as those from subjects with normal synovium (n = 28) were profiled by total RNA sequencing. RESULTS: Large differences in gene expression between RA and control biopsies (over 5000 genes) were identified. Despite clinical efficacy, the expression of a restricted set of less than 300 genes was reversed after 6 months of treatment. Many genes remained elevated, even in patients who achieved low disease activity. Interestingly, tDMARD downregulated genes included those involved in T cell activation and signaling and plasmablast/plasma cell differentiation and function. CONCLUSIONS: We have identified transcriptomic signatures that characterize synovial tissue from RA patients with early disease. Analysis after 6 months of tDMARD treatment highlight consistent alterations in expression of genes related to T cell activation and plasmablast/plasma cell differentiation. These results provide novel insight into the biology of early RA and the mechanism of tDMARD action and may help identify novel drug targets to improve rates of treatment-induced disease remission.
[Mh] Termos MeSH primário: Antirreumáticos/uso terapêutico
Artrite Reumatoide/tratamento farmacológico
Membrana Sinovial/efeitos dos fármacos
Linfócitos T/citologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Artroscopia
Biópsia
Estudos de Casos e Controles
Diferenciação Celular
Regulação para Baixo
Quimioterapia Combinada
Feminino
Seres Humanos
Hidroxicloroquina/uso terapêutico
Ativação Linfocitária/efeitos dos fármacos
Masculino
Metotrexato/uso terapêutico
Meia-Idade
Plasmócitos/citologia
Análise de Componente Principal
Indução de Remissão
Análise de Sequência de RNA
Sulfassalazina/uso terapêutico
Membrana Sinovial/metabolismo
Linfócitos T/efeitos dos fármacos
Transcriptoma
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antirheumatic Agents); 3XC8GUZ6CB (Sulfasalazine); 4QWG6N8QKH (Hydroxychloroquine); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183928


  7 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28859326
[Au] Autor:Konijn NPC; van Tuyl LHD; Boers M; den Uyl D; Ter Wee MM; van der Wijden LKM; Bultink IEM; Kerstens PJSM; Voskuyl AE; van Schaardenburg D; Nurmohamed MT; Lems WF
[Ad] Endereço:Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands.
[Ti] Título:Similar efficacy and safety of initial COBRA-light and COBRA therapy in rheumatoid arthritis: 4-year results from the COBRA-light trial.
[So] Source:Rheumatology (Oxford);56(9):1586-1596, 2017 Sep 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objective: To assess the efficacy and safety of initial COBRA-light vs COBRA therapy in RA patients after a 4-year follow-up period. Methods: In the COBRA-light trial, 162 consecutive patients with recent-onset RA were randomized to either COBRA-light (prednisolone and MTX) or COBRA therapy (prednisolone, MTX and SSZ) for 1 year. After 1 year, treatment was continued without protocol, and adjusted by the treating physician according to clinical judgement, preferably with a treat-to-target strategy. Four years after trial initiation, all patients were invited to participate in the COBRA-light extension study, in which patients were interviewed and physically examined, patient reported outcomes were assessed, radiographs were made and clinical records were examined for comorbidities and medication use. Results: In the extension study, 149 out of 162 (92%) original trial patients participated: 72 COBRA-light and 77 COBRA patients. Initial COBRA-light and COBRA therapy showed similar effect on disease activity, physical functioning, radiological outcome and Boolean remission over the 4-year follow-up period. In addition, both treatment groups showed similar survival and major comorbidities, although the power to detect differences was limited. Besides protocolled differences in prednisolone, MTX and SSZ use, the use of other synthetic and biologic DMARDs and intra-articular and intramuscular glucocorticoid injections was similar in both treatment groups over the 4-year period. Conclusion: Early RA patients initially treated with COBRA-light or COBRA therapy had similar efficacy and safety outcomes over a 4-year follow-up period.
[Mh] Termos MeSH primário: Antirreumáticos/uso terapêutico
Artrite Reumatoide/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antirreumáticos/administração & dosagem
Antirreumáticos/efeitos adversos
Artrite Reumatoide/diagnóstico por imagem
Comorbidade
Progressão da Doença
Esquema de Medicação
Quimioterapia Combinada
Feminino
Seguimentos
Seres Humanos
Masculino
Metotrexato/administração & dosagem
Metotrexato/efeitos adversos
Metotrexato/uso terapêutico
Meia-Idade
Prednisolona/administração & dosagem
Prednisolona/efeitos adversos
Prednisolona/uso terapêutico
Radiografia
Índice de Gravidade de Doença
Sulfassalazina/administração & dosagem
Sulfassalazina/efeitos adversos
Sulfassalazina/uso terapêutico
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antirheumatic Agents); 3XC8GUZ6CB (Sulfasalazine); 9PHQ9Y1OLM (Prednisolone); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170927
[Lr] Data última revisão:
170927
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170902
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex223


  8 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28667792
[Au] Autor:Otsubo K; Nosaki K; Imamura CK; Ogata H; Fujita A; Sakata S; Hirai F; Toyokawa G; Iwama E; Harada T; Seto T; Takenoyama M; Ozeki T; Mushiroda T; Inada M; Kishimoto J; Tsuchihashi K; Suina K; Nagano O; Saya H; Nakanishi Y; Okamoto I
[Ad] Endereço:Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
[Ti] Título:Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.
[So] Source:Cancer Sci;108(9):1843-1849, 2017 Sep.
[Is] ISSN:1349-7006
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Spliced variant isoforms of CD44 (CD44v) are a marker of cancer stem cells in solid tumors. They stabilize the xCT subunit of the transporter system xc(-) and thereby promote synthesis of the antioxidant glutathione. Salazosulfapyridine (SASP) is an inhibitor of xCT and suppresses the proliferation of CD44v-positive cancer cells. Chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer were enrolled in a dose-escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed. The primary end-point was the percentage of patients who experience dose-limiting toxicity. Fifteen patients were enrolled in the study. Dose-limiting toxicity was observed in one of six patients at a SASP dose of 1.5 g/day (elevation of aspartate and alanine aminotransferase levels, each of grade 3), two of five patients at 3 g/day (hypotension or pneumonitis, each of grade 3), and two of three patients at 4.5 g/day (anorexia of grade 3). The maximum tolerated dose was thus 3 g/day, and the recommended dose was 1.5 g/day. The overall response rate was 26.7% and median progression-free survival was 11.7 months, much longer than that for cisplatin-pemetrexed alone in previous studies. Exposure to SASP varied markedly among individuals according to ABCG2 and NAT2 genotypes. The serum concentration of free CD44v protein was increased after the first cycle of treatment, possibly reflecting death of cancer stem cells. Salazosulfapyridine was thus given safely in combination with cisplatin-pemetrexed, with the addition of SASP tending to prolong progression-free survival. This trial is registered in the UMIN Clinical Trials Registry as UMIN000017854.
[Mh] Termos MeSH primário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Protocolos de Quimioterapia Combinada Antineoplásica/farmacocinética
Protocolos de Quimioterapia Combinada Antineoplásica/toxicidade
Biomarcadores Tumorais/sangue
Carcinoma Pulmonar de Células não Pequenas/sangue
Carcinoma Pulmonar de Células não Pequenas/patologia
Cisplatino/administração & dosagem
Feminino
Seres Humanos
Receptores de Hialuronatos/sangue
Neoplasias Pulmonares/sangue
Neoplasias Pulmonares/patologia
Masculino
Dose Máxima Tolerável
Meia-Idade
Estadiamento de Neoplasias
Pemetrexede/administração & dosagem
Sulfassalazina/administração & dosagem
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (CD44 protein, human); 0 (Hyaluronan Receptors); 04Q9AIZ7NO (Pemetrexed); 3XC8GUZ6CB (Sulfasalazine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170702
[St] Status:MEDLINE
[do] DOI:10.1111/cas.13309


  9 / 3834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28397950
[Au] Autor:Aljahdali AH; Al-Buainain HM; Skarsgard ED
[Ad] Endereço:Department of Pediatric Surgery, King Fahad Hospital of the University, University of Dammam, Al Khobar, Kingdom of Saudi Arabia. E-mail. akramjahdali@gmail.com.
[Ti] Título:Staged closure of a giant omphalocele with amnion preservation, modified technique.
[So] Source:Saudi Med J;38(4):422-424, 2017 Apr.
[Is] ISSN:0379-5284
[Cp] País de publicação:Saudi Arabia
[La] Idioma:eng
[Ab] Resumo:Closure of a giant omphalocele can be challenging. Preservation of the amnion in staged closure is not commonly practiced. Here, we describe 2 cases of giant omphalocele treated with a modified amnion preservation, staged closure technique. This paper demonstrates the feasibility and safety of this technique, and the versatility of amnion to adapt to an escharization strategy if closure is not achievable.
[Mh] Termos MeSH primário: Hérnia Umbilical/cirurgia
[Mh] Termos MeSH secundário: Âmnio/cirurgia
Fasciotomia
Evolução Fatal
Seres Humanos
Hipertensão Pulmonar/complicações
Hipertensão Pulmonar/diagnóstico por imagem
Lactente
Masculino
Sulfadiazina/administração & dosagem
Sulfassalazina/administração & dosagem
Telas Cirúrgicas
Ventiladores Mecânicos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0N7609K889 (Sulfadiazine); 3XC8GUZ6CB (Sulfasalazine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171103
[Lr] Data última revisão:
171103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170412
[St] Status:MEDLINE
[do] DOI:10.15537/smj.2017.4.16240


  10 / 3834 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28390410
[Au] Autor:Nagahori M; Kochi S; Hanai H; Yamamoto T; Nakamura S; Omuro S; Watanabe M; Hibi T; OPTIMUM Study Group
[Ad] Endereço:Department of Gastroenterology, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyoku, Tokyo, 113-8519, Japan. nagahori.gast@tmd.ac.jp.
[Ti] Título:Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
[So] Source:BMC Gastroenterol;17(1):47, 2017 Apr 04.
[Is] ISSN:1471-230X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used. Aim of this study is to investigate real life results in using oral 5-ASA products for maintaining mild to moderate UC patients in Japan. METHODS: Adult UC outpatients treated with oral 5-ASA products were enrolled from 379 sites in Japan between July 2012 and July 2013, and followed for 52 weeks. Remission maintenance rate was evaluated by products and dosages. Factors affecting recurrence were also examined. RESULTS: A total of 5695 UC patients were registered. Among the 4677 patients in whom remission maintenance was observed, remission maintenance rate at week 52 was 80.2%. As for disease duration and dosage, Pentasa® 4000 mg/day in 2 divided doses was administered to 480 (21.0%) patients in remission and 341 (46.6%) patients in active stage, and Asacol® 3600 mg/day in 3 divided doses was administered to 696 (46.4%) patients in remission and 473 (67.3%) patients in active stage. The remission maintenance rate at week 52 by dosage and frequency did not significantly differ between Pentasa® Tablets at 4000 mg/day in 2 divided doses (76.5%) and Asacol® Tablets at 3600 mg/day in 3 divided doses (76.1%, P = 0.7868). Factors affecting the risk of relapse in UC were identified. Significantly persistent remission maintenance was noted in patients in whom duration of remission maintenance until enrollment was 12 to <24 months or ≥24 months relative to the reference category of <3 months (12 to <24 months: HR 0.600 [0.486-0.740], p < 0.0001]; ≥24 months: HR 0.352 [0.289-0.431], p < 0.0001). CONCLUSIONS: Efficacy of real life results in using oral 5-ASA products for maintaining mild to moderate UC patients was favorable. Maintaining remission for 12 months or longer after induction therapy was shown to reduce recurrence risk thereafter. TRIAL REGISTRATION: UMIN 000008563 (the date of registration: July 30, 2012), ClinicalTrials.gov NCT01654783 (the date of registration: July 30, 2012).
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico
Colite Ulcerativa/tratamento farmacológico
Mesalamina/uso terapêutico
Sulfassalazina/uso terapêutico
[Mh] Termos MeSH secundário: Administração Oral
Adulto
Idoso
Composição de Medicamentos
Feminino
Seres Humanos
Japão
Quimioterapia de Manutenção
Masculino
Meia-Idade
Recidiva
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 3XC8GUZ6CB (Sulfasalazine); 4Q81I59GXC (Mesalamine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170410
[St] Status:MEDLINE
[do] DOI:10.1186/s12876-017-0604-y



página 1 de 384 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde